Johnson & Johnson's orthopedics business reported flat worldwide sales in the third quarter of 2017.
While small gains were made in the hip and trauma business, the company reported larger declines in the spine and knee lines. Here is the breakdown for Johnson & Johnson's orthopedic sales:
1. Orthopedics overall: J&J reported $2.2 billion in third quarter sales, flat from the same period last year. For the nine months end, orthopedic sales were down 0.4 percent, driven by slow international sales.
2. Hips: Hip sales were up 1.5 percent for the quarter, hitting $328 million. The U.S. market drove hip sales with 2.6 percent growth over the same period last year. For the nine months end, hip sales were up 1.9 percent to $1 billion.
3. Knees: A huge drop — 6.8 percent — in international knee sales drove the 3.4 percent decline in worldwide knee sales for the third quarter. J&J reported $348 million in knee sales for the quarter and $1.1 billion for the nine months end, which was a 0.3 percent drop from the first nine months of 2016. U.S. knee sales dropped 1.3 percent in the quarter.
4. Trauma: Worldwide trauma sales were up 3.9 percent for the third quarter, hitting $662 million. As opposed to the company's knee sales, international trauma sales jumped 6.5 percent in the quarter to $264 million. For the nine months end, trauma sales grew 1.7 percent to nearly $2 billion.
5. Spine and other: U.S. spine sales suffered in the third quarter, declining 5.2 percent year-over-year. The drop in U.S. sales was partially offset by 1.8 percent growth in international spine and other sales, but worldwide sales were down 2.2 percent in the quarter, reaching just $918 million. For the nine months end, spine and other sales dropped 2.6 percent to $2.8 billion.